The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Data for APR-246 and azacitidine in patients with mTP53 MDS and AML
TP53 mutant (mTP53) myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) represent a molecular cohort with the poorest outcomes, as explained here by David Sallman, MD, of the Moffitt Cancer Center, Tampa, FL. Hypomethylating agents are the current standard of care for these patients; however, an alternative treatment is needed. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Sallman discusses the encouraging data from the Phase Ib/II trial of APR-246, a novel, small molecule that selectively induces apoptosis in mTP53 cancer cells, in combination with azacitidine.
